The effect of doxycycline temperature-sensitive hydrogel on inhibiting the corneal neovascularization induced by BFGF in rats

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 249, Issue 3, 2011, Pages 421-427

  Su, Wenru ^a   Li, Zhanrong ^a   Lin, Miaoli ^a   Li, Yongping ^a   He, Zixin ^b   Wu, Chuanbin ^b   Liang, Dan ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Cornea; Doxycycline; Neovascularization; Temperature sensitive hydrogel

Indexed keywords

DOXYCYCLINE; FIBROBLAST GROWTH FACTOR 2; INDIAN INK; SODIUM CHLORIDE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL DIAMETER; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DRUG EFFECT; DRUG RESPONSE; FEMALE; HYDROGEL; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RAT; TEMPERATURE SENSITIVITY; TREATMENT DURATION;

ADMINISTRATION, TOPICAL; ANGIOGENESIS INHIBITORS; ANIMALS; BETA-CYCLODEXTRINS; COLLAGENASES; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; DOXYCYCLINE; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; FIBROBLAST GROWTH FACTOR 2; POLOXAMER; RATS; RATS, SPRAGUE-DAWLEY; TEMPERATURE;

EID: 79955576498     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-010-1539-y     Document Type: Article

References (51)

1. Chang JH, Gabison EE, Kato T, Azar DT (2001) Corneal neovascularization. Curr Opin Ophthalmol 12:242-249 (Pubitemid 32751680)
2. Lim P, Fuchsluger TA, Jurkunas UV (2009) Limbal stem cell deficiency and corneal neovascularization. Semin Ophthalmol 24:139-148
3. Murata M, Nakagawa M, Takahashi S (1997) Inhibitory effects of plasminogen fragment on experimentally induced neovascularization of rat corneas. Graefes Arch Clin Exp Ophthalmol 235:584-586 (Pubitemid 27445365)
4. Kruse FE, Joussen AM, Rohrschneider K, Becker MD, Volcker HE (1998) Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol 236:461-466 (Pubitemid 28269042)
5. Joussen AM, Kruse FE, Volcker HE, Kirchhof B (1999) Topical application of methotrexate for inhibition of corneal angiogenesis. Graefes Arch Clin Exp Ophthalmol 237:920-927 (Pubitemid 29484167)
6. Joussen AM, Germann T, Kirchhof B (1999) Effect of thalidomide and structurally related compounds on corneal angiogenesis is comparable to their teratological potency. Graefes Arch Clin Exp Ophthalmol 237:952-961 (Pubitemid 30021284)
7. Klotz O, Park JK, Pleyer U, Hartmann C, Baatz H (2000) Inhibition of corneal neovascularization by alpha(v)-integrin antagonists in the rat. Graefes Arch Clin Exp Ophthalmol 238:88-93 (Pubitemid 30160508)
8. Cursiefen C, Wenkel H, Martus P, Langenbucher A, Nguyen NX, Seitz B, Kuchle M, Naumann GO (2001) Impact of short-term versus long-term topical steroids on corneal neovascularization after non-high-risk keratoplasty. Graefes Arch Clin Exp Ophthalmol 239:514-521 (Pubitemid 32725422)
9. Wu PC, Liu CC, Chen CH, Kou HK, Shen SC, Lu CY, Chou WY, Sung MT, Yang LC (2003) Inhibition of experimental angiogenesis of cornea by somatostatin. Graefes Arch Clin Exp Ophthalmol 241:63-69
10. Murata M, Shimizu S, Horiuchi S, Taira M (2006) Inhibitory effect of triamcinolone acetonide on corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 244:205-209
11. Peyman GA, Kivilcim M, Morales AM, DellaCroce JT, Conway MD (2007) Inhibition of corneal angiogenesis by ascorbic acid in the rat model. Graefes Arch Clin Exp Ophthalmol 245:1461-1467 (Pubitemid 47423328)
12. Bock F, Onderka J, Dietrich T, Bachmann B, Pytowski B, Cursiefen C (2008) Blockade of VEGFR3-signalling specifically inhibits lymphangiogenesis in inflammatory corneal neovascularisation. Graefes Arch Clin Exp Ophthalmol 246:115-119 (Pubitemid 350162691)
13. Azar DT (2006) Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 104:264-302
14. Ma DH, Chen JK, Kim WS, Hao YX, Wu HC, Tsai RJ, Hwang DG, Zhang F (2001) Expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in inflammation-induced corneal neovascularization. Ophthalmic Res 33:353-362 (Pubitemid 34015800)
15. Kvanta A, Sarman S, Fagerholm P, Seregard S, Steen B (2000) Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization. Exp Eye Res 70:419-428 (Pubitemid 30658885)
16. Sounni NE, Janssen M, Foidart JM, Noel A (2003) Membrane type-1 matrix metalloproteinase and TIMP-2 in tumor angiogenesis. Matrix Biol 22:55-61 (Pubitemid 36444507)
17. Ma DH, Zhang F, Shi W, Yao JY, Hsiao CH, Wu HC, Kim WS, Hao YX, Hwang DG, Chen JK, Tsai RJ (2003) Expression of tissue inhibitor of metalloproteinase-4 in normal human corneal cells and experimental corneal neovascularization. Ophthalmic Res 35:199-207 (Pubitemid 36736948)
18. Guerin C, Laterra J, Masnyk T, Golub LM, Brem H (1992) Selective endothelial growth inhibition by tetracyclines that inhibit collagenase. Biochem Biophys Res Commun 188:740-745
19. Sapadin AN, Fleischmajer R (2006) Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 54:258-265 (Pubitemid 43144395)
20. Ralph RA (2000) Tetracyclines and the treatment of corneal stromal ulceration: a review. Cornea 19:274-277
21. Dursun D, Kim MC, Solomon A, Pflugfelder SC (2001) Treatment of recalcitrant recurrent corneal erosions with inhibitors of matrix metalloproteinase-9, doxycycline and corticosteroids. Am J Ophthalmol 132:8-13 (Pubitemid 32600883)
22. Burns FR, Stack MS, Gray RD, Paterson CA (1989) Inhibition of purified collagenase from alkali-burned rabbit corneas. Invest Ophthalmol Vis Sci 30:1569-1575 (Pubitemid 19185960)
23. Smith VA, Cook SD (2004) Doxycycline-a role in ocular surface repair. Br J Ophthalmol 88:619-625 (Pubitemid 38526642)
24. Dan L, Shi-long Y, Miao-li L, Yong-ping L, Hong-jie M, Ying Z, Xiang-gui W (2008) Inhibitory effect of oral doxycycline on neovascularization in a rat corneal alkali burn model of angiogenesis. Curr Eye Res 33:653-660
25. Aydin E, Kivilcim M, Peyman GA, Esfahani MR, Kazi AA, Sanders DR (2008) Inhibition of experimental angiogenesis of cornea by various doses of doxycycline and combination of triamcinolone acetonide with low-molecular-weight heparin and doxycycline. Cornea 27:446-453 (Pubitemid 351591483)
26. Kenyon BM, Voest EE, Chen CC, Flynn E, Folkman J, D'Amato RJ (1996) A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci 37:1625-1632 (Pubitemid 26271414)
27. York M, Steiling W (1998) A critical review of the assessment of eye irritation potential using the Draize rabbit eye test. J Appl Toxicol 18:233-240 (Pubitemid 28360801)
28. Shan S, Lockhart AC, Saito WY, Knapp AM, Laderoute KR, Dewhirst MW (2001) The novel tubulin-binding drug BTO-956 inhibits R3230AC mammary carcinoma growth and angiogenesis in Fischer 344 rats. Clin Cancer Res 7:2590-2596
29. Norrby K (2006) In vivo models of angiogenesis. J Cell Mol Med 10:588-612
30. Ziche M, Morbidelli L (2009) The corneal pocket assay. Methods Mol Biol 467:319-329
31. Tong S, Chen Q, Shan SQ, Dewhirst MW, Yuan F (2006) Quantitative comparison of the inhibitory effects of GW5638 and tamoxifen on angiogenesis in the cornea pocket assay. Angiogenesis 9:53-58 (Pubitemid 44440549)
32. Cal K, Centkowska K (2008) Use of cyclodextrins in topical formulations: practical aspects. Eur J Pharm Biopharm 68:467-478 (Pubitemid 351318207)
33. El-Kamel AH (2002) In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate. Int J Pharm 241:47-55
34. Chen WL, Lin CT, Lin NT, Tu IH, Li JW, Chow LP, Liu KR, Hu FR (2009) Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis. Invest Ophthalmol Vis Sci 50:1659-1665
35. Kim SW, Ha BJ, Kim EK, Tchah H, Kim TI (2008) The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 15:e33-e38
36. Erdurmus M, Totan Y (2007) Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 245:1577-1579 (Pubitemid 47423342)
37. Bock F, Konig Y, Kruse F, Baier M, Cursiefen C (2008) Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 246:281-284 (Pubitemid 351149633)
38. Han YS, Lee JE, Jung JW, Lee JS (2009) Inhibitory effects of bevacizumab on angiogenesis and corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 247:541-548
39. Koenig Y, Bock F, Horn F, Kruse F, Straub K, Cursiefen C (2009) Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 247:1375-1382
40. Saravia M, Zapata G, Ferraiolo P, Racca L, Berra A (2009) Anti- VEGF monoclonal antibody-induced regression of corneal neovascularization and inflammation in a rabbit model of herpetic stromal keratitis. Graefes Arch Clin Exp Ophthalmol 247:1409-1416
41. Vassileva PI, Hergeldzhieva TG (2009) Avastin use in high risk corneal transplantation. Graefes Arch Clin Exp Ophthalmol 247:1701-1706
42. Lamoreaux WJ, Fitzgerald ME, Reiner A, Hasty KA, Charles ST (1998) Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc Res 55:29-42 (Pubitemid 28368411)
43. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2:737-744
44. Hashimoto G, Inoki I, Fujii Y, Aoki T, Ikeda E, Okada Y (2002) Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165. J Biol Chem 277:36288-36295
45. Seedor JA, Perry HD, McNamara TF, Golub LM, Buxton DF, Guthrie DS (1987) Systemic tetracycline treatment of alkali-induced corneal ulceration in rabbits. Arch Ophthalmol 105:268-271 (Pubitemid 17013713)
46. Perry HD, Golub LM (1984) Beneficial effect of systemic tetracycline therapy in the treatment of noninfected corneal ulcers. Cornea 3:75
47. Perry HD, Kenyon KR, Lamberts DW, Foulks GN, Seedor JA, Golub LM (1986) Systemic tetracycline hydrochloride as adjunctive therapy in the treatment of persistent epithelial defects. Ophthalmology 93:1320-1322 (Pubitemid 16008997)
48. De Paiva CS, Corrales RM, Villarreal AL, Farley WJ, Li DQ, Stern ME, Pflugfelder SC (2006) Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. Exp Eye Res 83:526-535
49. De Paiva CS, Corrales RM, Villarreal AL, Farley W, Li DQ, Stern ME, Pflugfelder SC (2006) Apical corneal barrier disruption in experimental murine dry eye is abrogated by methylprednisolone and doxycycline. Invest Ophthalmol Vis Sci 47:2847-2856 (Pubitemid 351639757)
50. Stone DU, Chodosh J (2004) Oral tetracyclines for ocular rosacea: an evidence-based review of the literature. Cornea 23:106-109 (Pubitemid 38031886)
51. Culbertson WW, Huang AJ, Mandelbaum SH, Pflugfelder SC, Boozalis GT, Miller D (1993) Effective treatment of phlyctenular keratoconjunctivitis with oral tetracycline. Ophthalmology 100:1358-1366 (Pubitemid 23274030)